A Singapore-based R&D company working to bring on the market the first homeopathic product with evidence-based label indication, and solve the unmet need in effective and safe flu treatment.
With positive results of preclinical studies and proof-of-concept clinical trial, GMP-compliant manufacturing ready for up-scaling, we are close to entering the EU market.
Product’s sales potential is $600M+.
We need $1.7M (€1.5M) to perform pivotal clinical trial and get the product registered in the EU.
After successful trial the product will be sold to a partner pharmaceutical company.
Strong IP protection would determine high value of the product for the IP buyer.
Company’s assets include: patents granted in USA, EU, China, Canada (pending in India); a catchy trade mark registered globally; web domain names; regulatory dossier documents.